We are live on ! Find out more
ADVM

Adverum Biotechnologies

Delisted

ADVM was delisted on the 8th of December, 2025.

76 hedge funds and large institutions have $62.3M invested in Adverum Biotechnologies in 2016 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 24 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more capital invested

Capital invested by funds: $49.8M → $62.3M (+$12.5M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

8% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 12

8% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 24

1% less funds holding

Funds holding: 7776 (-1)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $37K

Holders
76
Holders Change
-1
Holders Change %
-1.3%
% of All Funds
2.03%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
11
Increased
22
Reduced
24
Closed
12
Calls
Puts
$37K
Net Calls
-$37K
Net Calls Change
+$64K
Name Holding Trade Value Shares
Change
Change in
Stake
RA
26
Royce & Associates
New York
$380K -$383K -10,100 -52%
TC
27
TFS Capital
Pennsylvania
$319K -$310K -8,171 -51%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$277K +$25.2K +663 +11%
DMK
29
David M. Knott
$271K +$250K +6,600 New
California Public Employees Retirement System
30
California Public Employees Retirement System
California
$214K
GGHC
31
Gilder Gagnon Howe & Co
New York
$209K -$38 -1 -0%
California State Teachers Retirement System (CalSTRS)
32
California State Teachers Retirement System (CalSTRS)
California
$200K +$1.9K +50 +1%
JP Morgan Chase
33
JP Morgan Chase
New York
$196K +$58.6K +1,546 +48%
PP
34
PDT Partners
New York
$165K -$24.3K -640 -14%
PPA
35
Parametric Portfolio Associates
Washington
$142K +$21K +553 +19%
Goldman Sachs
36
Goldman Sachs
New York
$135K -$132K -3,485 -52%
TA
37
Teachers Advisors
New York
$126K -$23.1K -609 -17%
ProShare Advisors
38
ProShare Advisors
Maryland
$116K -$19.6K -516 -15%
Charles Schwab
39
Charles Schwab
California
$116K
RhumbLine Advisers
40
RhumbLine Advisers
Massachusetts
$102K +$1.9K +50 +2%
AllianceBernstein
41
AllianceBernstein
Tennessee
$100K -$7.21K -190 -7%
Dimensional Fund Advisors
42
Dimensional Fund Advisors
Texas
$92K +$16.1K +425 +24%
RG
43
Redmile Group
California
$91K
TSS
44
Two Sigma Securities
New York
$87K +$80.6K +2,124 New
JMPWA
45
JP Morgan Private Wealth Advisors
California
$82K
New York State Common Retirement Fund
46
New York State Common Retirement Fund
New York
$74K
NFA
47
Nationwide Fund Advisors
Ohio
$68K +$7.93K +209 +15%
IAM
48
Integre Asset Management
New York
$64K +$58.7K +1,548 New
CS
49
Credit Suisse
Switzerland
$60K -$133K -3,505 -71%
Wells Fargo
50
Wells Fargo
California
$59K

ADVM Hedge Fund Activity: Q3 2016 in Review

76 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q3 2016, worth a combined $62.3M — up 25% from $49.8M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of ADVM and 11 opened new positions — a net loss of 1 holder — while 24 trimmed existing stakes and 22 added.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $3.59M. The largest seller was Great Point Partners, exiting entirely with an estimated $1.74M sold.

  • 76 institutional investors held Adverum Biotechnologies (ADVM) as of Q3 2016, down from 77 in Q2 2016.
  • Funds reported $62.3M of Adverum Biotechnologies stock for Q3 2016, up 25% quarter-over-quarter.
  • 11 funds opened new Adverum Biotechnologies positions in Q3 2016 and 12 closed out, a net change of -1 holder.
  • The largest Adverum Biotechnologies buyer in Q3 2016 was EcoR1 Capital, an estimated $3.59M added.
  • The largest Adverum Biotechnologies seller in Q3 2016 was Great Point Partners, an estimated $1.74M sold.

Based on aggregated 13F filings for Q3 2016.